Good 10-year performance for St Jude's heart valve:
This article was originally published in Clinica
Executive Summary
St Jude Medical has announced positive results for a 10-year follow-up study of its stentless tissue heart valve. The Toronto SPV valve, which was approved by the US FDA in 1997, was designed to improve the haemodynamic performance and extend durability over conventional stented tissue valves. The study of 447 patients found that, regarding durability, 88% of patients did not need a new valve implant. Also, 95% of patients were free of valve related deaths by the end of the study. According to the St Paul, Minnesota firm, clinical performance was maintained and patient satisfaction was high.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.